AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Name Might 11, 2026 5:00 PM EDT
Firm Individuals
Tryn Stimart – Chief Authorized Officer, Chief Compliance Officer, Company Secretary & Privateness Officer
Carl L. Hansen – CEO, President & Chairperson
Sarah Noonberg – Chief Medical Officer
Andrew Sales space – Chief Monetary Officer
Convention Name Individuals
Stephen Willey – Stifel, Nicolaus & Firm, Included, Analysis Division
Evan Seigerman – BMO Capital Markets Fairness Analysis
Srikripa Devarakonda – Truist Securities, Inc., Analysis Division
Allison Bratzel – Piper Sandler & Co., Analysis Division
Brendan Smith – TD Cowen, Analysis Division
Debanjana Chatterjee – JonesTrading Institutional Providers, LLC, Analysis Division
Steven Seedhouse – Cantor Fitzgerald & Co., Analysis Division
Presentation
Operator
Good afternoon, and welcome to AbCellera’s Q1 2026 Enterprise Replace Convention Name. My title is Ben, and I’ll facilitate the audio portion of right this moment’s interactive broadcast. [Operator Instructions] Presently, I wish to flip the decision over to Tryn Stimart, AbCellera’s Chief Authorized and Compliance Officer. It’s possible you’ll proceed.
Tryn Stimart
Chief Authorized Officer, Chief Compliance Officer, Company Secretary & Privateness Officer
Thanks. Hiya, everybody. Thanks for becoming a member of us for AbCellera’s First Quarter 2026 Earnings Name. I am Tryn Stimart, AbCellera’s Chief Authorized and Compliance Officer. Dr. Carl Hansen, AbCellera’s President and CEO; Dr. Sarah Noonberg, AbCellera’s Chief Medical Officer; and Andrew Sales space, AbCellera’s Chief Monetary Officer, are talking on right this moment’s name.
Throughout this name, we might make statements about our strategic priorities and monetary outlook based mostly on our present expectations and in accordance with the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. Our statements are topic to plenty of dangers, uncertainties and different elements that might trigger precise outcomes to vary materially from these described. Please assessment the Danger Elements part of our most up-to-date Type 10-Ok and subsequent 10-Q filings with the SEC for
